Drug Trial Radar · NCT04480762
A Trial of SHR-1703 in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Nov 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Aug 4, 2020
Primary completion
Sep 21, 2021
Study completion Sep 21, 2021
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
SHR-1703 is a monoclonal antibody under development for severe asthma. This study is the first study in Healthy subjects. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose SHR-1703 administered subcutaneously in Chinese healthy subjects.
Conditions
- Asthma
Interventions
SHR-1703Drug
SHR-1703
PlaceboDrug
Placebo of the SHR-1703
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse events (AEs) and serious adverse events (SAEs)Time frame: From Day 1 to Days 155
- Safety as determined by abnormality in haematologyTime frame: From Day 1 to Days 155
- Safety as determined by abnormality in clinical chemistryTime frame: From Day 1 to Days 155
- Safety as determined by abnormality in urinalysisTime frame: From Day 1 to Days 155
- Safety as determined by evaluation of blood pressure in mmHgTime frame: From Day 1 to Days 155
- Safety as determined by evaluation of Pulse rate in beats per minuteTime frame: From Day 1 to Days 155
- Safety as determined by evaluation of body temperature in degree CelsiusTime frame: From Day 1 to Days 155
- Safety as determined by evaluation of Respiratory rate in beats per minuteTime frame: From Day 1 to Days 155
- Safety as determined by analysis of 12-lead ECG variables: heart rate (beats per minute)Time frame: From Day 1 to Days 155
- Safety as determined by analysis of 12-lead ECG variables: PR, QRS, QT and QTcF (milliseconds)Time frame: From Day 1 to Days 155
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.